Nan Yu1,2, Bo Zhang2, Mei Xu1, Sheng Wang2, Rong Liu2, Jianli Wu2, Jing Yang1, Ling Feng2. 1. Reproductive Medical Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. 2. Obstetrics and Gynecology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Abstract
PROBLEM: Intrauterine administration of autologous peripheral blood mononuclear cells (PBMCs) activated by HCG in vitro was reported to improve implantation rates in patients with repeated failure of IVF-ET (in vitro fertilization-embryo transfer). In this article, the value of intrauterine administration of PBMCs before embryo transfer and its optimal cell culture method will be investigated. METHOD OF STUDY: Patients who had not experienced successful pregnancy despite three or more IVF-ET sessions were enrolled in this study (n=240, 240 cycles). PBMCs were obtained from patients themselves and were cultured with HCG for 24 hours. Twenty-four hours later, PBMCs were then administered to the intrauterine cavity of that patient from the study group (n=93, 93 cycles). The control group (n=105, 105 cycles) underwent ET without intrauterine administration. RESULTS:Clinical pregnancy rate, implantation rate, and miscarriage rate in the PBMC-treated group (46.24% and 23.66%, n=43 and 22, respectively) were significantly higher than those in the non-treated group (20.95% and 11.43%, P<.05; n=22 and 12, respectively). CONCLUSION: These findings indicate that intrauterine administration of autologous PBMC activated by HCG in vitro effectively improves embryo implantation in patients with three or more IVF failures.
RCT Entities:
PROBLEM: Intrauterine administration of autologous peripheral blood mononuclear cells (PBMCs) activated by HCG in vitro was reported to improve implantation rates in patients with repeated failure of IVF-ET (in vitro fertilization-embryo transfer). In this article, the value of intrauterine administration of PBMCs before embryo transfer and its optimal cell culture method will be investigated. METHOD OF STUDY: Patients who had not experienced successful pregnancy despite three or more IVF-ET sessions were enrolled in this study (n=240, 240 cycles). PBMCs were obtained from patients themselves and were cultured with HCG for 24 hours. Twenty-four hours later, PBMCs were then administered to the intrauterine cavity of that patient from the study group (n=93, 93 cycles). The control group (n=105, 105 cycles) underwent ET without intrauterine administration. RESULTS: Clinical pregnancy rate, implantation rate, and miscarriage rate in the PBMC-treated group (46.24% and 23.66%, n=43 and 22, respectively) were significantly higher than those in the non-treated group (20.95% and 11.43%, P<.05; n=22 and 12, respectively). CONCLUSION: These findings indicate that intrauterine administration of autologous PBMC activated by HCG in vitro effectively improves embryo implantation in patients with three or more IVF failures.
Authors: Lea S Lentz; Annika J Stutz; Nicole Meyer; Kristin Schubert; Isabel Karkossa; Martin von Bergen; Ana C Zenclussen; Anne Schumacher Journal: Front Immunol Date: 2022-09-20 Impact factor: 8.786